Effect of anti-4-azoquinoline 1-oxide antibody on immunosuppression by 4-hydroxyaminoquinoline 1-oxide.
D000287:Administration, Topical; D000681:Amylases / Q000276:immunology; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D000917:Antibody Formation / Q000187:drug effects; D000941:Antigens; D001391:Azo Compounds / Q000494:pharmacology; D001412:Bacillus subtilis / Q000201:enzymology; D001798:Blood Proteins; D002352:Carrier Proteins / Q000276:immunology; D003497:Cyclic N-Oxides / Q000276:immunology* / Q000494:pharmacology; D003877:Dermatitis, Contact / Q000276:immunology; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006241:Haptens; D006386:Hemagglutination Tests; D006898:Hydroxylamines / Q000276:immunology; D007111:Immunity, Cellular / Q000187:drug effects*; D007116:Immunization, Passive; D007165:Immunosuppression Therapy; D007279:Injections, Subcutaneous; D051379:Mice; D010047:Ovalbumin / Q000494:pharmacology; D010853:Picryl Chloride / Q000276:immunology; D011804:Quinolines / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology; D011817:Rabbits / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D000941:Antigens; D001391:Azo Compounds; D001798:Blood Proteins; D002352:Carrier Proteins; D003497:Cyclic N-Oxides; D006241:Haptens; D006898:Hydroxylamines; D011804:Quinolines; D010047:Ovalbumin; D000681:Amylases; D010853:Picryl Chloride